← Eichor
Condition: Mrna Vaccine Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mrna Vaccine

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Parti
Phase 2 · 8 location(s) · ModernaTX, Inc. · NCT07561294A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Phase 4 · 6 location(s) · ModernaTX, Inc. · NCT06585241Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
Phase 1/Phase 2 · 1 location(s) · Sinovac Biotech Co., Ltd · NCT07400003NWRD09 for HPV-16 Related Cervical HSIL
Phase 1 · 1 location(s) · Newish Biotech (Wuxi) Co., Ltd. · NCT07047989A Study to Learn About mRNA Vaccines Against Influenza in Adults
Phase 2 · 15 location(s) · Pfizer · NCT07431853Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Sub
Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06026800Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · Jinling Hospital, China · NCT06326736XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
NA · 1 location(s) · Wu Wenming · NCT06353646Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 · 10 location(s) · Epitopea Ltd · NCT07665515Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
Phase 1/Phase 2 · 7 location(s) · Sanofi · NCT06891417An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized S
EARLY_Phase 1 · 3 location(s) · ANRS, Emerging Infectious Diseases · NCT07605520Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07067385Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.
EARLY_Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06928922To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With H
Phase 1 · 2 location(s) · Shenzhen Xinhe Biomedical · NCT07594964A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region
Phase 1 · 1 location(s) · Newish Biotech (Wuxi) Co., Ltd. · NCT07710664Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Phase 1 · 1 location(s) · Sichuan University · NCT07004244Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
EARLY_Phase 1 · 1 location(s) · Ruijin Hospital · NCT06577532A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
Phase 1 · 12 location(s) · GlaxoSmithKline · NCT07464314Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplas
Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06019702A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA
Phase 2 · 6 location(s) · BioNTech SE · NCT07379580A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid
Phase 1/Phase 2 · 3 location(s) · SK Bioscience Co., Ltd. · NCT06680128Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NA · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06141369Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · Ruijin Hospital · NCT06496373Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Phase 1 · 2 location(s) · West China Hospital · NCT07040943Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults
Phase 1/Phase 2 · 5 location(s) · ANRS, Emerging Infectious Diseases · NCT06821126Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07583654A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activ
Phase 1 · 1 location(s) · Xingchen Peng · NCT07100210Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06026774Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06195384A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07306299
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.